NCT06356194已完成1 期
A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Drug-Drug Interaction Potential Between Bemnifosbuvir/Ruzasvir and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy®) in Healthy Adult Subjects
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- PK of Biktarvy (BIK: Bictegravir, tenofovir alafenamide, emtricitabine) on the pharmacokinetics (PK) of Bemnifosbuvir (BEM) and Ruzasvir (RZR).
研究概览
简要总结
Drug-drug interaction study of Biktarvy and Bemnifosbuvir/Ruzasvir
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug.
- •Minimum body weight of 50 kg and body mass index (BMI) of 18-30 kg/m
- •Willing to comply with the study requirements and to provide written informed consent.
排除标准
- •Infected with hepatitis B virus, hepatitis C virus, HIV or SARS-CoV-
- •Abuse of alcohol or drugs.
- •Use of other investigational drugs within 28 days of dosing.
- •Concomitant use of prescription medications, or systemic over-the-counter medications.
- •Other clinically significant medical conditions or laboratory abnormalities.
结局指标
主要结局
PK of Biktarvy (BIK: Bictegravir, tenofovir alafenamide, emtricitabine) on the pharmacokinetics (PK) of Bemnifosbuvir (BEM) and Ruzasvir (RZR).
时间窗: Day 2, Days 4-7, Days 14-17, Days 21-24
Maximum plasma concentration (Cmax) and Area under the plasma concentration-time curve (AUC)
To determine the effect of Bemnifosbuvir (BEM)/Ruzasvir (RZR) combination on the PK of Biktarvy (BIK: Bictegravir, tenofovir alafenamide, emtricitabine)
时间窗: Days 7-10, Day 12, Days 14-17, Days 21-24.
Maximum plasma concentration (Cmax) and Area under the plasma concentration-time curve (AUC)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Drug-drug Interaction Study of Ruzasvir and BemnifosbuvirHealthy Volunteer StudyNCT05731843Atea Pharmaceuticals, Inc.32
已完成
1 期
A Study of PBI-200 With Ritonavir or Cobicistat in Healthy VolunteersDrug-drug InteractionNCT05692570Pyramid Biosciences21
已完成
1 期
The Study of Bemnifosbuvir in Healthy Japanese SubjectsHealthy Volunteer StudyNCT05905497Atea Pharmaceuticals, Inc.14
已完成
1 期
Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and RifampinDrug Drug InteractionNCT06031454Guangdong Raynovent Biotech Co., Ltd56
已完成
3 期
Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV InfectionHepatitis CNCT01896193Gilead Sciences127